GO
Loading...

Enter multiple symbols separated by commas

Stocks Novartis AG

More

  • Early movers: TRV, UTX, VZ, RF, DEPO, NKE & more Tuesday, 21 Jul 2015 | 8:04 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • European shares fall, pulled down by drugmakers Tuesday, 21 Jul 2015 | 7:51 AM ET

    *Pharmaceuticals drop after Novartis results. LONDON, July 21- European shares retreated on Tuesday from their six-week high in the previous session, with the healthcare leading the market lower after Novartis reported quarterly incomes below analysts' expectations. Novartis dropped 2.1 percent after the Swiss drugmaker reported a weak performance by its...

  • Novartis' now offers generic MS drug: CEO Tuesday, 21 Jul 2015 | 6:13 AM ET
    Novartis' now offers generic MS drug: CEO

    Joe Jimenez, Novartis CEO, discusses the generic availability of its multiple-sclerosis drug Copaxone.

  • Novartis' new heart drug potential game changer: CEO Tuesday, 21 Jul 2015 | 6:09 AM ET
    Novartis' new heart drug potential game changer: CEO

    Joe Jimenez, Novartis CEO, discusses the pharma company's quarterly results and its new heart failure drug, Entresto.

  • *Gold gains after plunging over 4 pct to 5- yr lows. LONDON, July 21- Gold prices steadied on Tuesday after plunging more than 4 percent in recent sessions, but remained under pressure as the dollar touched a three-month high on firming expectations of an interest rate hike. "Greece may be easing us into the quieter summer months, however there is still plenty to focus...

  • July 21- Novartis remains bullish about prospects for its blockbuster cancer drug Afinitor, which achieved sales of $1.58 billion last year, despite competitors lining up to challenge its market position. The success of Opdivo could, therefore, push back the use of Afinitor as doctors try the newer option, reducing sales of the Novartis product.

  • *Novartis leads market lower after results. LONDON, July 21- European shares edged lower on Tuesday after hitting a six-week high in the previous session, with the healthcare sector leading the market lower after Novartis reported quarterly incomes below analysts' expectations. The STOXX Europe 600 Healthcare Index fell 1.0 percent, the top sectoral decliner...

  • BERLIN— Swiss-based pharmaceutical giant Novartis' second-quarter net income dropped 32 percent over the same quarter last year, brought down primarily by poor performance from associated companies and negative effects of a strong U.S. dollar, the company said Tuesday. Group sales are expected to grow by mid-single digits and operating income is expected...

  • Strong dollar hits Novartis; reports profit miss Tuesday, 21 Jul 2015 | 3:06 AM ET

    Swiss drugmaker Novartis reported second-quarter core net income that fell short of expectations on Tuesday, on the back of a stronger dollar.

  • Looking at bolt-on acquisitions: Novartis CEO Tuesday, 21 Jul 2015 | 1:45 AM ET
    Looking at bolt-on acquisitions: Novartis CEO

    Joe Jimenez, CEO of Novartis, says the company is looking for bolt-on acquisitions worth between $1 bilion to $3 billion, rather than mega-mergers.

  • Tuesday focus: Commodities crush vs earnings Monday, 20 Jul 2015 | 6:28 PM ET
    A trader works on the floor of the New York Stock Exchange.

    A gusher of corporate earnings reports could set the tone for stocks Tuesday, as traders keep an eye on the increasingly sloppy commodities markets.

  • *Paulson expected to put pressure on Syngenta board. July 15- Hedge fund Paulson& Co has taken a stake in Syngenta AG and could push for the Swiss pesticide maker's board to accept a takeover offer from U.S. seed company Monsanto Co, people familiar with the matter said. Monsanto, the world's largest seed company, has made a $45 billion bid for Syngenta that the Swiss...

  • July 13- Anacor Pharmaceuticals Inc's experimental skin ointment succeeded in late-stage studies, taking the drugmaker a step closer to having a potential blockbuster in its portfolio and raising expectations that it could be taken over. "Personally, I'd love to see Anacor independent a little bit longer, but I don't think its going to happen," said Paul Yook,...

  • Gene therapy for deafness moves a few steps closer Wednesday, 8 Jul 2015 | 2:00 PM ET

    *Novartis tests gene therapy in adults with damaged hearing. Separately, a clinical trial backed by Novartis is under way to help a different group of people who have lost their hearing through damage or disease. "We are somewhat late in the auditory field but I think we are getting there now," said Tobias Moser of the University Medical Center Gottingen, Germany, who...

  • *Euro STOXX 50 up 1 pct, fell 4 pct in last two sessions. LONDON, July 8- European stocks rebounded on Wednesday, lifted by a rise in heavyweight financial and pharmaceutical shares, while politicians gave Greece more time for a deal to avoid having to leave the euro. Barclays rose 2 percent as investors welcomed the bank's decision to dump its chief executive, while...

  • Early movers: HOG, TSLA, WWE, MSFT, BCS & more Wednesday, 8 Jul 2015 | 7:42 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • TEL AVIV, July 8- As Israel's biggest company Teva strives to get even bigger by swallowing up rival Mylan for more than $40 billion, further down the food chain a raft of upstart life science firms are struggling to climb onto the global ladder. Israel has a burgeoning life science industry comprising around 1,380 mostly very small companies.

  • *Barclays climbs after ousting CEO. *Novartis rises after U.S. regulatory boost. British bank Barclays and Swiss pharmaceuticals group Novartis were among the best performers, with investors welcoming Barclays' decision to dump its chief executive while Novartis got a boost from regulators.

  • Novartis news goes straight to the heart Wednesday, 8 Jul 2015 | 6:00 AM ET
    Novartis news goes straight to the heart

    Novartis wins FDA approval for new combination drug Entresto to treat heart failure.

  • *Novartis may offer pay-for-performance deals. July 7- Novartis AG on Tuesday won U.S. approval for its keenly awaited new heart failure drug Entresto earlier than expected, boosting hopes for a medicine tipped by analysts to reap billions of dollars in annual sales. Novartis is looking to Entresto to help revive its fortunes in heart medicine as the blood...